MSMohamed Sedky

Mohamed Sedky

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mohamed Sedky has a total of 48 co-authors. Here are the top co-authors by number of shared publications:

  • Iman Zaky

    Radiology Department, National Cancer Institute, Children’s Cancer Hospital Egypt, Cairo University

    5 shared publications
  • Alaa ElHaddad

    CCHE: Children's Cancer Hospital Egypt 57357, and Pediatric Oncology Dpt, National Cancer Institute Cairo University

    4 shared publications
  • Hala Taha

    CCHE: Children's Cancer Hospital Egypt 57357, and Pathology Dpt National Cancer Institute, Cairo University

    4 shared publications
  • Asmaa Salama

    Pathology Department, National Cancer Institute, Children’s Cancer Hospital Egypt, Cairo University

    3 shared publications
  • Omayma Hassanein

    Department of Clinical Research, Children’s Cancer Hospital 57357 (11617), Cairo, Egypt

    3 shared publications
  • Emad E. Salama

    Department of Pediatrics, National Research Centre

    2 shared publications

Latest Publications

  • Open Access

    Structural and functional hepatic factors as prognostic indicators in children with Langerhans cell histiocytosis

    by Seham Hassan, Mohamed Sedky M Sedky, Asmaa Salama, Iman Zaky, Hany Girguis, Salma Abd Elkarim, Alaa Elhaddad

    Background and aim: Langerhans cell histiocytosis (LCH) is a clonal myeloid neoplasm with variable outcomes; hepatic involvement is uniformly classified as high-risk. However, liver disease includes distinct structural and biochemical phenotypes with unclear prognostic significance. This study aimed to identify prognostic determinants in pediatric hepatic LCH, define phenotype-specific risk, and assess whether Z-score–standardized liver size independently predicts disease course and treatment response. Methods: This retrospective study included 453 children with LCH treated at Children’s Cancer Hospital, Egypt, between 2007 and 2021. Patients received the LCH-III protocol before 2012 and the LCH-IV protocol thereafter. Liver involvement was evaluated using baseline biochemical tests and ultrasonography, and liver span Z-scores were calculated to standardize hepatomegaly. Results: Eighty patients had hepatic involvement: 27 presented with hepatomegaly and preserved liver function, while 53 had hepatic dysfunction. Hepatic dysfunction independently predicted initial treatment failure (OR 9.28; 95% CI, 2.21–64.3; p = 0.001) and was associated with markedly inferior 5-year overall survival (OS) (39.4% vs 92.6%) and event-free survival (EFS) (12.9% vs 70.4%) compared with those with hepatomegaly and preserved function (all p< 0.0001). In addition, hypoalbuminemia emerged as an adverse biochemical prognostic factor (HR 4.40; 95% CI, 1.52–12.7; p = 0.003). Multivariable analysis demonstrated that week 6 non-response was the only independent predictor of both OS (HR 3.17; 95% CI, 1.37–7.31; p = 0.007) and EFS (HR 9.26; 95% CI, 4.12–20.84; p< 0.001). Conversely, outcomes were not affected by the extent of hepatomegaly, suggesting that liver size alone does not confer prognostic significance in the absence of functional hepatic impairment. Conclusions: In pediatric LCH, hepatic dysfunction, rather than hepatomegaly, emerges as the true determinant of high-risk liver involvement. Lake of early response at week 6 independently predicts inferior outcomes. Children with preserved liver function demonstrate excellent outcomes irrespective of liver size. These findings suggest potential refinement of current risk definitions and support a shift toward function-based risk stratification, pending validation in larger, multicenter prospective studies.

  • Open Access

    High Risk Langerhans Cell Histiocytosis in Children: The role of salvage in improving the outcome. A single center experience.

    by Mohamed Sedky Sedky, Asmaa Hamoda, Hala Taha, Iman Zaky, Omayma Hassanain, Alaa ElHaddad

    Background: In pediatric multi-system high risk organs (RO+) Langerhans cell histiocytosis (LCH), failing 1st line treatment has the highest mortality. Hereby we aim to present the outcome of salvage whether due to disease progression (DP) at end of induction or afterwards reactivation (REA). Sixty-seven RO+ LCH patients, treated between mid-2007 and end 2019 were retrospectively analyzed. They were subjected to the LCH III protocol era, having 1st line intermediate dose methotrexate induction (ID MTX) but without salvage by 2-Cda based regimen (2-CdABR) and that of LCH IV protocol without ID MTX but with 2-CdABR salvage. Results: Twenty-two patients showed DP. Of them 9 received 2-CdABR where 5 patients survived in better status. All the remaining 13 not receiving 2-CdABR died. Otherwise, 20 patients showed REA (RO+ mode n=12). Out of those 8 patients receiving 2-CdABR for REA RO+ mode, only one survived in better status. The overall survival (OS) of those undergoing DP was 27% CI 14-54 versus REA 67% CI 49-93 p 0.004. OS of DP with 2-CdABR was 56% CI=31-97.7 versus without 8 % CI 2-51, p<0.001. While OS of REA with 2-CdABR was 38% CI=13-100 versus without 74 % CI 53-100 p value 0.7. Conclusion: 2-CdABR rescued DP RO+LCH in relation to regimen without. Its impact on REA remains controversial in relation to other salvage regimen.

  • Open Access

    Pediatric pulmonary multisystem langerhans cell histiocytosis: does lung lesion severity affect the outcome?

    by Mohamed Sedky, Seham Gohar, Sonia Ahmed, Iman Zaky, Asmaa Salama, Omayma Hassanein, Eslam Maher, Alaa ElHaddad

    Background: The pediatric pulmonary multisystem Langerhans cell histiocytosis (PPM LCH) is associated with either low risk or high risk organ(s). The nodulo-cystic lung lesions although pathognomonic, yet are very variable in severity and remain a source of controversy in certifying pulmonary LCH diagnosis. The study aimed to examine the prognostic value of clinical respiratory manifestations and radiological lung lesions severity. This is through associating a CT chest triad of bilateral, extensive and diffuse lesions. It is a retrospective study of 350 LCH patients who received systemic treatment at Children’s Cancer Hospital Egypt during the period from 2007 to 2020. Results: Sixty-seven patients (67/350–19.1%) had PPM LCH at presentation. Severe lung lesions were present in 24 of them. The median follow-up period was 61 months (IQR: 3.4–8.3). The 5-year overall survival (OS) and event free survival (EFS) was 89% and 56.6% respectively. The EFS, for severe radiological lesions triad was 38% ± 20.7 versus 66% ± 16.2 for non-severe lesions triad p 0.002, while for presence of chest X-ray changes 27% ± 22.344 versus absence of chest X ray changes 66% ± 14.7 p 0.001, for clinical respiratory manifestations 13% ± 13.9 versus none 62% ± 22.9 p < 0.001, for RO− with severe lung lesions 47% ± 30.4 versus RO− without severe lung lesions 69% ± 5.9 p 0.04. There was a tendency for the independent prognostic impact of severe lung involvement; aHR = 1.7 (95% CI 0.92–3.13, p = 0.09). Conclusion: Although the lung is a low -risk organ per se in LCH, our study demonstrates a non negligeable prognostic impact of severe lung involvement in the risk stratification of pediatric LCH. This warrants further study and external validation.


  • Open Access

    Pediatric Pulmonary Multisystem Langerhans cell histiocytosis. Does lung lesion severity affect the outcome?

    by Mohamed Sedky, Seham Gohar, Sonia Ahmed, Iman Zaky, Asmaa Salama, Omayma Hassanein, Eslam Maher, Alaa ElHaddad

    Background Pulmonary involvement in pediatric multisystem Langerhans cell histiocytosis (PPM LCH) is associated with either low risk (RO-) or high risk (RO+) organs. The nodulo-cystic lung lesions although pathognomonic, yet are very variable in severity and remain a source of controversy in certifying pulmonary LCH diagnosis. The study aimed to examine the prognostic value of clinical respiratory distress and radiological lung lesions severity. This is through associating a CT chest triad of bilateral, extensive and diffuse lesions. It is a retrospective study of 350 LCH patients who received systemic treatment at Children’s Cancer Hospital Egypt during the period from 2007 to 2020. Results Sixty-seven patients (67/350 − 19.1%) had PPM LCH at presentation. Severe lung lesions were present in 24 of them. The median follow-up period was 61 months (IQR: 3.4 to 8.3). The 5-year overall survival (OS) and event free survival (EFS) was 89% and 56.6% respectively. The EFS, for severe radiological lesions triad was 38% ± 20.7 versus 66% ± 16.2 for non-severe lesions p 0.002, while for concordant chest CT positive / X ray positive lesions 27% ± 22.344 versus discordant CT positive/X ray negative 66% ± 14.7 p 0.001, for clinical respiratory distress 13% ± 13.9 versus none 62% ± 22.9 p < 0.001, for RO- with severe lung lesions 47% ± 30.4 versus RO- without severe lung 69% ± 5.9 p0.04. There was a tendency for the independent prognostic impact of severe lung involvement; aHR = 1.7 (95% CI: 0.92 to 3.13, p = 0.09). Conclusion Although the lung is a low -risk organ per se in LCH, our study demonstrates a non negligeable prognostic impact of severe lung involvement in the risk stratification of pediatric LCH. This warrants further study and external validation.

  • Outcome of High-risk Langerhans Cell Histiocytosis (LCH) in Egyptian Children, Does Intermediate-dose Methotrexate Improve the Outcome?

    by Mohamed S. Sedky, Asmaa Hamouda, Hala Taha, Iman Zaky, Omayma Hassanain, Ahmed El Hemaly, Alaa ElHaddad

    High-risk multisystem organ (RO+) Langerhans cell histiocytosis (LCH) has the least survival. We present the outcome of RO+ LCH in a pediatric single center. Fifty RO+ LCH patients, treated between 07/2007 and 07/2015, were retrospectively analyzed. Induction vinblastine (VBL) and prednisone (PRED) with intermediate-dose methotrexate (idMTX) was adopted until 2012 (n=20) wherein idMTX was omitted (n=30). The 3-year overall survival (OS) of MTX and non-MTX groups was 75% and 63%, respectively, P=0.537, while the event-free survival (EFS) was 36.9% and 13.2%, respectively, P=0.005. At week 12 of induction, “better status” was obtained in 80% of those receiving MTX, and 55% of those who were not. The statistically significant factors associated with both poor OS and EFS were trihemopoietic cytopenias, hepatic dysfunction, tri RO+ combination, and single induction. The factors associated with disease progression (DP) on induction were trihemopoietic cytopenias, hepatic dysfunction, and lack of idMTX, while those for disease reactivations (REA), the season of autumn/winter, lung disease, male sex, and idMTX were the associated factors. The 1-year OS was remarkably affected with the occurrence of DP versus REA versus none, wherein it was 47%, 93%, and 95%, respectively, P=0.001. In conclusion, idMTX is associated with better EFS. DP on induction remains of dismal prognosis in relation to disease REA afterwards. Risk stratification should highlight the role of trihemopoietic cytopenias, hepatic dysfunction, tri RO+, central nervous system risk site, and lung association.


  • Langerhans Cell Histiocytosis (LCH) in Egyptian Children: Does Reactivation Affect the Outcome?

    by Mohamed Sedky Mahmoud Sedky, Hany Abdel Rahman, Emad Moussa, Hala Taha, Tarek Raafat, Omayma Hassanein


  • Cytomegalovirus Infection in Pediatric Allogenic Hematopoietic Stem Cell Transplantation. A Single Center Experience

    by M. Sedky, Y. Mekki, V. Mialou, N. Bleyzac, S. Girard, E. Salama, H. Abdel Rahman, Y. Bertrand

    We report a retrospective analysis of Cytomegalovirus (CMV) infection: incidence, recurrence, resistance, and subsequent disease of 81 children who underwent allogenic hematopoietic stem cell transplantation (HSCT). The recipient and/or donor's CMV serology was positive prior to transplant [recipient (R+) and/or donor (D+)]. CMV was monitored by RT-PCR starting from the first week post transplant. Forty patients showed CMV infection (49, 5%). Of them 10 manifested CMV disease leading to four deaths. In univariate analysis, factors associated with CMV infection were CMV R+ P < .01, CMV R+/D+ pair P < .01, nonbone marrow (BM) stem cell source P < .05, nonirradiation conditioning regimen P < .05, Antithymocyte globulin (ATG) P < .01. Factors associated with CMV resistance were: >1 HLA allele mismatch P < .05, CMV R +/D–pair P < .01, CMV D–P < .01, non-BM P < .05, nongenoidentical transplant P < .01. CMV disease was influenced by >1 HLA allele mismatch (P < .001), non-BM (P < .01). On multivariate analysis, CMV R+/D− (P < .05), corticosteroids ≥2 mg/kg P < .01, ATG P < .01 and non-BM (P < .05) were independent factors for CMV infection. CMV R+ transplant is associated with more CMV infection and resistance to preemptive treatment. Prolonged immune suppression (IS) worsens outcome of CMV infection and should be shortened whenever possible.


  • Open Access

    Outcome of pediatric parameningeal rhabdomyosarcoma. The Children Cancer Hospital, Egypt, experience

    by Hany Abdel Rahman, Mohamed Sedky, Inas Mohsen, Hala Taha, Iman Loaye, Mohamed S. Zaghloul, Madiha El Wakeel, Rania M. Labib

    PM RMS represents a diagnostic and therapeutic problem as it is less visible than other superficial head and neck sites, and has tendency to local and intracranial extension. The aim of this work is to study the treatment outcome, overall survival (OS) and event free survival (EFS) of pediatric PM RMS patients diagnosed and treated at the Children Cancer Hospital-Egypt [CCHE-57357] during a 4 year period. Retrospective review of charts of newly diagnosed pediatric PM RMS patients diagnosed and treated in CCHE during the period between July 2007 and the end of June 2011. Forty-two pediatric patients with PM RMS with age ranging from 3 months to 17.7 years (median 6.9 years) were studied. The follow up period ranged from 4 to 55 months with a median of 24.8 months. Twenty-one patients [50%] were stage III, while 11 patients [26.1%] were stage IV. The 3-year overall survival (OS) was 58.4 ± 8.9%. OS was 65.9 ± 10% for non metastatic tumors while it was 35.8 ± 16.2% for the metastatic ones (p=0.039). The 3-year event-free survival (EFS) was 48 ± 8.6% for the whole group. The non-metastatic and metastatic patients had 3-year EFS of 56.5 ± 9.7% and 24.9 ± 14.9% respectively. This difference was not statistically significant (p=0.127). PM RMS remains a diagnostic and therapeutic problem. Late presentation and advanced local disease compromise treatment options and decrease OS and EFS.


  • Pediatric Palliative Care in the Middle East

    by Michael Silbermann, Maha Arnaout, Hany Abdel Rahman Sayed, Mohamed Sedky, Mohammad El-Shami, Myriam Ben-Arush, Salma Al-Hadad, Huda Abu-Saad Huijer, Barbara Pitsillides, Nurdan Tacyildiz, et al.


  • Comparative study of two mechlorethamine, vincristine, procarbazine, and prednisone derived chemotherapeutic protocols for the management of pediatric Hodgkin lymphoma (HL): single-center 5-year experience

    by Youssef Al-Tonbary, Mohamed M. Sarhan, Rasha A. El-Ashry, Emad Salama, Mohamed Sedky, Ashraf Fouda

    We aimed for the comparison of two protocols (OAP and COMP) as chemotherapy treatment in children with Hodgkin lymphoma (HL). A total of 119 children newly diagnosed with HD were divided to receive either the anthracycline-based OAP protocol or the alkylating-agent-based COMP protocol. Sixty patients received the OAP protocol and 59 patients received the COMP protocol. Complete response was achieved for 81.4% of patients treated with the COMP protocol versus 53.3% for those who received the OAP treatment. Toxic hepatitis or liver cell failure was recorded in 5% of patients treated with the COMP protocol. Complications were more frequent in those treated with the OAP protocol, as 6.8% developed heart failure and 20% showed toxic hepatitis or liver cell failure. The relapse rate was almost equal in both treatment arms. Patients treated with the COMP protocol achieved a better response and less toxicity but with similar survival to those given the OAP protocol.